These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7521089)

  • 21. Inhibition of calcium oxalate monohydrate (COM) crystal growth by pyrophosphate, citrate and rat urine.
    Sidhu H; Gupta R; Thind SK; Nath R
    Urol Res; 1986; 14(6):299-303. PubMed ID: 3027939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium oxalate crystal growth in the presence of mucin.
    Akbarieh M; Tawashi R
    Scanning Microsc; 1991 Dec; 5(4):1019-26; discussion 1026-7. PubMed ID: 1822027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental model to study sedimentary kidney stones.
    Grases F; Llobera A
    Micron; 1998; 29(2-3):105-11. PubMed ID: 9684348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The development of continuous crystallizer and observation of formation and growth of calcium oxalate crystals].
    Suzuki K; Domiki C; Tsugawa R
    Hinyokika Kiyo; 1991 Jun; 37(6):569-75. PubMed ID: 1716408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth.
    Martin X; Werness PG; Bergert JH; Smith LH
    J Urol; 1984 Oct; 132(4):786-8. PubMed ID: 6206244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring calcium oxalate crystallization: a constant composition approach.
    Kolbach-Mandel AM; Kleinman JG; Wesson JA
    Urolithiasis; 2015 Oct; 43(5):397-409. PubMed ID: 26016572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Citrate, not phosphate, can dissolve calcium oxalate monohydrate crystals and detach these crystals from renal tubular cells.
    Chutipongtanate S; Chaiyarit S; Thongboonkerd V
    Eur J Pharmacol; 2012 Aug; 689(1-3):219-25. PubMed ID: 22713548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulatory effect of the 23-kD calcium oxalate monohydrate binding protein on calcium oxalate stone formation during oxalate stress.
    Asokan D; Kalaiselvi P; Varalakshmi P
    Nephron Physiol; 2004; 97(1):p23-30. PubMed ID: 15153748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dual role of polyelectrolytes and proteins as mineralization promoters and inhibitors of calcium oxalate monohydrate.
    Campbell AA; Ebrahimpour A; Perez L; Smesko SA; Nancollas GH
    Calcif Tissue Int; 1989 Aug; 45(2):122-8. PubMed ID: 2476205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Artificial simulation of renal stone formation. Influence of some urinary components.
    Grases F; Costa-Bauzá A; March JG; Söhnel O
    Nephron; 1993; 65(1):77-81. PubMed ID: 8413796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does urinary oxalate interfere with the inhibitory role of glycosaminoglycans and semisynthetic sulfated polysaccharides in calcium oxalate crystallization?
    Cao LC; Deng G; Boevé ER; Romijn JC; de Bruijn WC; Verkoelen CF; Schröder FH
    Eur Urol; 1997; 31(4):485-92. PubMed ID: 9187912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium pentosan polysulphate--a novel inhibitor of urinary risk factors and enzymes in experimental urolithiatic rats.
    Senthil D; Malini MM; Varalakshmi P
    Ren Fail; 1998 Jul; 20(4):573-80. PubMed ID: 9713875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Studies of sodium pentosan polysulphate (SPP) therapy on the urinary stone disease. Experimental studies on the calcium oxalate crystallization and the effects in healthy subjects].
    Fukatani T
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):246-53. PubMed ID: 1710303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate crystallization in vitro and in vivo.
    Norman RW; Scurr DS; Robertson WG; Peacock M
    Clin Sci (Lond); 1985 Mar; 68(3):369-71. PubMed ID: 2578913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The solubility of calcium oxalates explains some aspects of their underrepresentation in the oral cavity.
    Vincent KM; Azzopardi PV; Mittler S; Grohe B
    Arch Oral Biol; 2021 Jan; 121():104965. PubMed ID: 33157495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former.
    Hess B; Jordi S; Zipperle L; Ettinger E; Giovanoli R
    Nephrol Dial Transplant; 2000 Mar; 15(3):366-74. PubMed ID: 10692522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N; Jansen B; Hesse A
    Urol Res; 2002 Oct; 30(5):336-41. PubMed ID: 12389124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins.
    Hess B; Nakagawa Y; Coe FL
    Am J Physiol; 1989 Jul; 257(1 Pt 2):F99-106. PubMed ID: 2750929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agglomeration of calcium oxalate monohydrate in synthetic urine.
    Grases F; Masárová L; Söhnel O; Costa-Bauzá A
    Br J Urol; 1992 Sep; 70(3):240-6. PubMed ID: 1422681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration.
    Cao LC; Boevé ER; Schröder FH; Robertson WG; Ketelaars GA; de Bruijn WC
    J Urol; 1992 Jun; 147(6):1643-6. PubMed ID: 1593714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.